* DUPIXENT ® is the only biologic medicine approved by Health Canada to treat moderate-to-severe atopic dermatitis. * Public reimbursement under the Ontario Exceptional Access Program and the New ...

MISSISSAUGA, ON, June 17, 2021 /CNW/ - Sanofi Canada announced today that a new 300 mg single-dose (single-use) pre-filled pen for DUPIXENT ® (dupilumab injection) is now available in Canada. The ...

TORONTO, Oct. 22, 2025 /CNW/ - Health Canada has approved Dupixent® (dupilumab injection) as an add-on maintenance treatment in adult patients with chronic obstructive pulmonary disease (COPD) ...

An experimental oral Janus kinase 1 (JAK1) inhibitor, abrocitinib, showed greater itch reduction after 2 weeks of treatment than dupilumab in patients with moderate to severe atopic dermatitis (AD), ...

Ultraviolet (UV) light, either UVB or UVA, in combination with a photosensitizing agent is used for the treatment of AD much in the way UV light is used for treatment of psoriasis. Phototherapy is ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Individuals with severe type 2 asthma and chronic rhinosinusitis with nasal polyps may benefit from the biologic treatment, dupilumab. A study on the efficacy of the biologic drug, dupilumab, found ...

Please provide your email address to receive an email when new articles are posted on . IL-13, which dupilumab blocks, induces nitric oxide production, which leads to mucus hypersecretion. At week 24, ...

An oral Janus kinase 1 (JAK1) inhibitor, upadacitinib (Rinvoq), relieves the symptoms of atopic dermatitis (AD) better than dupilumab (Dupixent), researchers say. "The differences between the two ...

Compared with placebo, dupilumab treatment resulted in statistically significant and meaningful symptom improvements in adults and adolescents with eosinophilic esophagitis (EoE), according to ...

Please provide your email address to receive an email when new articles are posted on . The NIH launched a clinical trial to assess whether dupilumab can reduce asthma exacerbations and improve lung ...